Opinion|Videos|August 8, 2024
Esketamine for TRD: MOA, Application, and Adverse Events
Robert Zalewski-Zaragoza, MD expands on the option of esketamine for treatment resistant depression, highlighting the unique mechanism of action and application.
Advertisement
Advertisement
Related to this article
Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.
Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
Advertisement
Advertisement
Trending on HCPLive
1
Finerenone Outperforms Spironolactone, Eplerenone in HFpEF, HFmrEF Renal Outcomes
2
Hidradenitis Suppurativa Care: Expectations, Comorbidities, and Wound Care
3
Fall Clinical 2026 First Half Recap: Psoriasis, Atopic Dermatitis, and More
4
Why Early Advanced Therapy Matters in Hidradenitis Suppurativa
5